Telix Pharmaceuticals
Price & Volume
Stats
See more52W Range | $6.28-$18.49 |
Market Cap | $3.2B |
Shares Short | 217,298 |
Financials
See moreRevenue (12 Mos) | $803.7M |
Revenue Growth (YoY) | 49.3% |
Gross Profit (12 Mos) | $381.8M |
Diluted EPS | -$0.02 |
News
See moreYahoo Finance • 16 days ago
EDAP | Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate Cancer
Yahoo Finance • 30 days ago
OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
Yahoo Finance • last month
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
Yahoo Finance • 2 months ago
Telix And Regeneron Partner To Advance Next-Generation Radiopharmaceutical Therapies
About
CEO | Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., Ph.D |
Address | 55 Flemington Road, North Melbourne, VIC, Australia, 3051 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 1,120 |